Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

• Published in: European heart journal. Cardiovascular pharmacotherapy Vol. 9; no. 1; pp. 38 - 46
• Main Authors: Esteve-Pastor, María A, Rivera-Caravaca, José M, Roldán, Vanessa, Sanmartin Fernández, Marcelo, Arribas, Fernando, Masjuan, Jaime, Barrios, Vivencio, Cosin-Sales, Juan, Freixa-Pamias, Román, Recalde, Esther, Pérez-Cabeza, Alejandro I, Manuel Vázquez Rodríguez, José, Ràfols Priu, Carles, Anguita Sánchez, Manuel, Lip, Gregory Y H, Marin, Francisco
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.01.2023
• Subjects: Aged; Aged, 80 and over; Anticoagulants; Atrial fibrillation; Atrial Fibrillation - diagnosis; Atrial Fibrillation - drug therapy; Calibration; Cardiac arrhythmia; Complications and side effects; Female; Health risks; Hemorrhage; Hemorrhage - chemically induced; Hemorrhage - epidemiology; Humans; Male; Medical research; Medicine, Experimental; Middle Aged; Pharmaceutical industry; Prospective Studies; Registries; Risk Assessment - methods; Risk Factors; Rivaroxaban; Rivaroxaban - adverse effects; United Kingdom; United States; Germany; Spain; HAS-BLED; Bleeding risk; ORBIT; Bleeding scores; Atrial fibrillation

Abstract Background Assessing bleeding risk during the decision-making process of starting oral anticoagulation (OAC) therapy in atrial fibrillation (AF) patients is essential. Several bleeding risk scores have been proposed for vitamin K antagonist users but, few studies have focused on validation...